Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel
Jacob A. Doll(University of Washington), Keith A.A. Fox(University of Edinburgh), Paul W. Armstrong(Canadian VIGOUR Centre), Megan L. Neely(Duke University), E. Magnus Ohman(Tarzana Treatment Centers), Matthew T. Roe(Clinical Research Institute), Harvey D. White(University of Auckland), Suman Duvvuru(Eli Lilly (United States)), Scott S. Sundseth, Paul A. Gurbel(Sinai Hospital), Kenneth J. Winters(Eli Lilly (United States)), Deepak L. Bhatt(Mount Sinai Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Dorairaj Prabhakaran(Dignity Health)
Cited by 39
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k